> He has an investor for USD 1 million for a Phase 1 cancer drug and is struggling.
Well, the market is betting on the fact that Phase 1 trials for such critical drugs can be fully modeled on digital twins running on GPUS, so they can leapfrog needing human subjects for RCTs.
Not disagreeing with you, though.